低至中危主动脉瓣狭窄患者TAVI与SAVR治疗的个体参与者数据荟萃分析
该研究纳入4项随机对照试验的2873例低至中危重度症状性主动脉瓣狭窄患者,采用个体参与者数据荟萃分析比较TAVI与SAVR的1年结局。主要终点为全因死亡或任何卒中,TAVI组风险低于SAVR组(HR 0.73,95%CI 0.56-0.95)。总体荟萃分析(8项RCT)HR为0.76(95%CI 0.60-0.97),提示TAVI可作为低至中危患者的替代选择。
要点
- 低至中危重度症状性主动脉瓣狭窄患者中,TAVI与1年全因死亡或任何卒中风险降低相关。
- 个体参与者数据荟萃分析显示主要终点HR为0.73(95%CI 0.56-0.95)。
- 总体荟萃分析(8项RCT)主要终点HR为0.76(95%CI 0.60-0.97)。
核心结论
- 在4项RCT的个体参与者数据荟萃分析及8项RCT的总体荟萃分析中,TAVI与低至中危重度症状性主动脉瓣狭窄患者1年全因死亡或任何卒中发生率降低相关。
研究设计与样本
- 研究检索MEDLINE数据库至2025年6月15日,纳入比较TAVI与SAVR的随机对照试验。
- 个体参与者数据荟萃分析纳入4项研究者发起的RCT(DEDICATE、NOTION、NOTION-2、UK TAVI),共2873例患者,平均年龄76.7岁(SD 5.5),男性805例(56.1%),随机分配至TAVI(n=1439)或SAVR(n=1434)。
- 采用1阶段和2阶段个体参与者数据荟萃分析,并加入产业资助RCT的聚合数据进行总体荟萃分析。
主要发现
- 1年主要终点(全因死亡或任何卒中)TAVI对比SAVR的风险比在1阶段分析中为0.73(95%CI 0.56-0.95),在2阶段分析中为0.79(95%CI 0.49-1.27)。
- 2阶段总体荟萃分析中主要终点风险比为0.76(95%CI 0.60-0.97)。
- 次要终点包括全因死亡、任何卒中、致残性卒中、心血管死亡、心血管原因再住院、心肌梗死、新发心房颤动、新永久起搏器植入和主动脉瓣再干预。
临床怎么用
- 对于低至中危重度症状性主动脉瓣狭窄患者,TAVI可作为外科主动脉瓣置换术的替代选择。
局限性
- 需要长期随访以评估这些发现的可持续性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Mounting evidence suggests transcatheter aortic valve implantation (TAVI) as preferred treatment for patients at low to intermediate surgical risk. However, limitations in study design and statistical power raise concerns about the generalizability of individual randomized clinical trials (RCTs) comparing TAVI and surgical aortic valve replacement (SAVR) to routine clinical practice. OBJECTIVE: To compare 1-year outcomes of TAVI vs SAVR in patients with severe symptomatic aortic stenosis at low to intermediate surgical risk applying a 2-stage individual participant data (IPD) and aggregate meta-analyses. DATA SOURCES: MEDLINE databases were searched for RCTs comparing TAVI and SAVR in patients with aortic stenosis until June 15, 2025. STUDY SELECTION: RCTs were selected comparing TAVI vs SAVR in patients with severe symptomatic aortic stenosis at low or intermediate surgical risk with 1-year follow-up. DATA EXTRACTION AND SYNTHESIS: IPD were obtained from all investigator-initiated RCTs (DEDICATE, NOTION, NOTION-2, and UK TAVI) and analyzed in 1- and 2-stage IPD meta-analyses. An overall meta-analysis was performed by adding aggregate data from industry-sponsored RCTs. MAIN OUTCOMES AND MEASURES: The primary end point was all-cause death or any stroke 1 year after randomization. Secondary end points included all-cause death, any stroke, disabling stroke, cardiovascular death, rehospitalization for cardiovascular cause, myocardial infarction, new-onset atrial fibrillation, new permanent pacemaker implantation, and aortic valve reintervention. RESULTS: The IPD meta-analysis included 4 RCTs comprising 2873 patients (mean [SD] age, 76.7 [5.5] years; 805 [56.1%] male) at low to intermediate surgical risk randomly assigned to TAVI (n = 1439) or SAVR (n = 1434). At 1 year, the hazard ratio (HR) for the primary end point for TAVI compared to SAVR was 0.73 (95% CI, 0.56-0.95) in the 1-stage and 0.79 (95% CI, 0.49-1.27) in the 2-stage IPD meta-analysis. In the 2-stage overall meta-analysis the HR for the primary end point was 0.76 (95% CI, 0.60-0.97). CONCLUSIONS AND RELEVANCE: In this IPD meta-analysis of 4 RCTs, and an overall meta-analysis of 8 RCTs of patients with severe symptomatic AS at low to intermediate risk, TAVI was associated with a reduction in the 1-year incidence of all-cause death or any stroke. These findings emphasize TAVI as alternative option in patients at low to intermediate risk. Long-term follow-up is warranted to evaluate sustainability of these findings.
引用
- Ludwig S, Klimek M, Bay B, et al. Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk: An Individual Participant Data Meta-Analysis. JAMA Cardiol. 2025. PMID: 40884787. doi:10.1001/jamacardio.2025.3403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。